Alzheon to present new clinical data and analyses for ALZ-801

The presentations highlight Alzheon’s ‘precision medicine’ approach to drug development for Alzheimer’s disease.

Alzheon will be making four presentations at the 13th International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2017) in Vienna, Austria, 29 March-2 April 2017.

The presentations highlight Alzheon’s ‘precision medicine’ approach to drug development for Alzheimer’s disease, based on individual genetic and biological information. The company’s clinical program for ALZ-801 is supported by clinical analyses published in late 2016 showing a gene-dose effect associating efficacy of an amyloid-targeted agent with the APOE4 genetic status in patients with Alzheimer’s disease (AD). The publication described clinical analyses from over 2,000 patients in Phase III tramiprosate studies showing promising efficacy in AD patients homozygous for the epsilon 4 allele of apolipoprotein E (APOE4/4 patients). The new analyses to be presented at AD/PD 2017 build further on this data and help refine the target population for future confirmatory studies.

The oral presentations are as follows:

• ALZ-801: Efficient Alzheimer’s Disease Modification by Preventing Formation of Toxic Amyloid Aggregates
• Persistent Efficacy of Tramiprosate in APOE4 Homozygous AD Subjects Treated Over 130 Weeks: Results of North American Extension Study
• Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Versus Moderate Patients
• ALZ-801 Brain Penetration, PK/PD Analyses and Clinical Dose Projection Form Basis for Confirmatory Phase 3 in Alzheimer's Disease